A study done by the researchers suggests spreading of type 2 diabetes (T2D) through blood transfusions or toxic meat as a result of misshapen protein seeds. The protein seeds are similar to those associated with the spreading of mad cow disease to humans from cattle. Authors say spreading of type 2 diabetes (T2D) is easier in humans compared to spreading brain diseases (such as mad cow disease) with the consumption of "rogue" proteins present in animal products. Spreading of brain diseases is not easy as brain contains blood-brain barrier (BBB), which divides fluid in central nervous system and brain from circulating blood.
Islet amyloid polypeptide (IAPP) in cattle and other large animals are structurally similar to humans. Earlier studies have noticed deposits of misshapen protein or islet amyloid polypeptide (IAPP) in more than 90 percent of the diabetes patients. These islet amyloid polypeptide (IAPP) protein seeds are similar in those humans who carry mad cow disease. Researchers speculate the spread of rogue proteins between species.
The researchers have conducted experiments with genetically modified mice models by injecting them with toxic clusters. They observed development of all type 2 diabetes (T2D) symptoms in them within weeks. They also noticed similar chemical signature when toxic clusters were added to pancreatic tissue of a healthy human in a dish. Researchers are yet to identify good evidence that shows type 2 diabetes (T2D) is contagious and the type 2 diabetes (T2D) development mechanism working in mice models will apply in humans too. Now the research team is investigating the possibility of acquiring of type 2 diabetes (T2D) with the consumption of "rogue" proteins present in animal products.
Senior author of the study was Christopher J. Soto, Associate Professor of Psychology, Colby College, Waterville, Maine, United States. The study was published on August 1, 2017, in the Journal of Experimental Medicine. Title of the article was "Induction of IAPP amyloid deposition and associated diabetic abnormalities by a prion-like mechanism."
A study done by the researchers at the University College London, United Kingdom shows prevention of Parkinson's disease with an exenatide drug. Researchers have conducted trials for 48 weeks duration among 62 Parkinson's patients with either placebo or with a weekly injection of exenatide drug, but without stopping their regular Parkinson's disease medications. The trial includes 12 weeks wash-out period.
The 60 weeks duration trial results show improvements to the Parkinson's disease severity scores significantly among patients under exenatide drug trial and worsening disease severity scores among patients under placebo. The results show promising treatment option for Parkinson's disease with exenatide diabetes drug. As the current study was small, researchers say longer-term studies are required with larger participants before considering exenatide diabetes drug as a viable treatment option for Parkinson's disease.
The study was funded by The Michael J. Fox Foundation for Parkinson's Research, New York, United States. Co-author of the study was Dr. Thomas Foltynie, PhD, Professor of Neurology, National Hospital for Neurology and Neurosurgery, University College London. The study findings were published on August 3, 2017, in The Lancet journal. Title of the article was "Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial."
Exenatide : Exenatide drug is a weekly injection, which is being prescribed as Bydureon. It is a glucagon-like peptide-1 (GLP-1) drug used by type 2 diabetes (T2D) patients to lower high blood sugar levels. The drug lowers sugar levels by increasing insulin secretion, reducing appetite and preventing the action of glucagon.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.